WHO classification of CNS tumours
Updates to Article Attributes
The WHO classification of CNS tumours is the most widely accepted system for classifying CNS tumours and was based on the histological characteristics of the tumour. Although the most recent version of the 'blue book' is the 4th edition from 2007, an update has been released in 2016 3, which should be considered a replacement of the earlier version. "At this point, a decision to undertake the 5th edition series of WHO Blue Books has not been made" 3. This 2016 update has, for the first time, included molecular parameters into the diagnostic schema, and in fact has elevated them in some instances above histological features 3.
This is a fairly dry article, primarily for reference. For more readable versions, see the article on brain tumours and brain tumours in infancy for general discussion of these topics.
Main changes since previous (2007) version
The most recent update (2016) has significantly changed the classification of a number of tumour families, introducing a greater reliance on molecular markers. The most notable changes involve diffuse gliomas, in which IDH status (mutated vs wildtype) and 1p19q co-deletion (for oligodendrogliomas) have risen to prominence. Importantly if histological phenotype and genotype are not-concordant (e.g. looks like diffuse astrocytoma but is 1p19q co-deleted, ATRX-wildtype) then genotype wins and it is used to determine diagnosis 3.
Medulloblastomas have also been divided into distinct molecular subgroups.
Another change is the combining of solitary fibrous tumours of the dura with hemangiopericytoma, which although appearing very different on imaging seem now to be manifestations of the same tumour.
Classification
Explanatory notes
- four digit code: is from the International Classification of Disease for Oncology (ICD-O)
- /: the number after the slash (/) refers to biological behaviour, not WHO Grade
- *: refers to a 'new' tumour in the classification
- italics: refers to a provisional inclusion
- NOS: not otherwise specified
Diffuse astrocytic and oligodendroglial tumours
- WHO grade II
-
diffuse astrocytoma
- IDH-mutant - 9400/3
- gemistocytic astrocytoma - 9411/3
- IDH-wildtype - 9400/3
- NOS - 9400/3
- IDH-mutant - 9400/3
- oligoastrocytoma NOS - 9382/3
-
oligodendroglioma - 9450/3
- IDH-mutant, 1p19q co-deleted
- NOS
-
diffuse astrocytoma
- WHO grade III
-
anaplastic astrocytoma - 9401/3
- IDH-mutant
- IDH-wildtype
- NOS
- anaplastic oligoastrocytoma NOS - 9382/3
-
anaplastic oligodendroglioma - 9451/3
- IDH-mutant, 1p19q co-deleted
- NOS
-
anaplastic astrocytoma - 9401/3
- WHO grade IV
-
glioblastoma
-
IDH wildtype - 9440/3
- giant cell glioblastoma - 9441/3
- gliosarcoma 9442/3
- epithelioid glioblastoma - 9440/3
- IDH mutant - 9440/3 *
- NOS - 9440/3
-
IDH wildtype - 9440/3
-
glioblastoma
- diffuse midline glioma, H3K27M-mutant *
Other astrocytic tumour
- WHO grade I
- pilocytic astrocytoma 9421/11 - WHO grade I
- subependymal giant cell astrocytoma 9384/1 - WHO grade I
- WHO grade II
- pilomyxoid astrocytoma 9425/3
- pleomorphic xanthoastrocytoma 9424/3 - WHO grade II
- WHO grade III
- anaplastic pleomorphic xanthoastrocytoma 9424/3 - WHO grade III
Ependymal tumours
- WHO grade I
- subependymoma - 9383/1
- myxopapillary ependymoma - 9394/1
- WHO grade II
-
ependymoma - 9391/3
- papillary ependymoma
- clear cell ependymoma
- tanycytic ependymoma
- RELA fusion-positive - 9396/3 *
-
ependymoma - 9391/3
- WHO grade III
- anaplastic ependymoma - 9392/3
Other gliomas
- WHO grade I
- angiocentric glioma - 9431/1
- WHO grade II
- WHO grade IV
- astroblastoma - 9430/3
Choroid plexus tumours
- WHO grade I
- choroid plexus papilloma - 9390/0
- WHO grade II
- atypical choroid plexus papilloma - 9390/1
- WHO grade III
- choroid plexus carcinoma - 9390/3
Neuronal and mixed neuronal-glial tumours
- WHO grade I
- desmoplastic infantile astrocytoma and ganglioglioma - 9412/1
- dysembryoplastic neuroepithelial tumour (DNET) - 9413/0
- dysplastic gangliocytoma of cerebellum - (Lhermitte-Duclos) - 9493/0
- gangliocytoma - 9492/0
- ganglioglioma - 9505/1
- papillary glioneuronal tumor - 9509/1
- paraganglioma of the filum terminale - 8680/1
- rosette-forming glioneuronal tumour of the fourth ventricle - 9509/1
- WHO grade II
- central neurocytoma - 9506/1
- extraventricular neurocytoma - 9506/1
- cerebellar liponeurocytoma - 9506/1
- WHO grade III
- anaplastic ganglioglioma - 9505/3
- WHO grade unknown
- diffuse leptomeningeal glioneuronal tumour - no IDC-O code *
Tumours of the pineal region
- WHO grade I
- pineocytoma - 9361/1
- WHO grade II or III
- WHO grade IV
- pineoblastoma - 9362/3
Embryonal tumours
- WHO grade IV
-
medulloblastoma
-
genetically defined
- WNT-activated - 9475/3 *
- SHH-activated & TP53-mutant - 9476/3
- medulloblastoma SHH-activated & TP53-wildtype - 9471/3
- group 3 - 9477/3
- group 4 - 9477/3
- histologically defined
- classic - 9470/3
- desmoplastic/nodular - 9471/3
- extensive nodularity - 9471/3
- large cell/anaplastic - 9470/3
- NOS - 9470/3
-
genetically defined
-
medulloblastoma
- CNS neuroblastoma 9500/3
- CNS ganglioneuroblastoma 9490/3
-
embryonal tumors with multilayered rosettes - 9478/3 *
- C19MC-altered
- NOS
- medulloepithelioma 9501/3
- atypical teratoid / rhabdoid tumour 9508/3
- CNS embryonal tumour with rhabdoid features 8508/3
- CNS embryonal tumour, NOS 9473/3
Tumours of cranial and paraspinal nerves
- WHO grade I
- schwannoma (neurilemoma, neurinoma) - 9560/0
-
neurofibroma - 9540/0
- atypical neurofibroma - 9540/0
- plexiform neurofibroma - 9550/0
- perineurioma 9571/0
- WHO grade II, III or IV
-
malignant peripheral nerve sheath tumour (MPNST) - 9540/3
- epithelioid
- with perineural differentiation
-
malignant peripheral nerve sheath tumour (MPNST) - 9540/3
Tumours of meningothelial cells
- WHO grade I
- meningioma - 9530/0
- meningothelial meningioma - 9531/0
- fibrous meningioma - 9532/0
- microcystic meningioma - 9530/0
- psammomatous meningioma - 9533/0
- angiomatous meningioma - 9534/0
- secretory meningioma - 9530/0
- metaplastic meningioma - 9530/0
- lymphoplasmacyte-rich meningioma - 9530/0
- WHO grade II
- atypical meningioma - 9539/1
- clear cell meningioma - 9538/1
- chordoid meningioma - 9538/1
- WHO grade III
- anaplastic meningioma (malignant) - 9530/3
- papillary meningioma - 9538/3
- rhabdoid meningioma - 9538/3
Mesenchymal, non-meningothelial tumours
- WHO grade I, II or III
- solitary fibrous tumour of the dura / haemangiopericytoma - 8815/0 /1 /3
- WHO grade I
- angiolipoma - 8861/0
- chondroma - 9220/0
- desmoid-type fibromatosis - 8821/1
- haemangioblastoma - 9161/1
- haemangioma - 9120/0
- hibernoma - 8880/0
- leiomyoma - 8890/0
- lipoma - 8850/0
- myofibroblastoma - 8825/0
- osteochondroma - 9210/0
- osteoma 9180/0
- rhabdomyoma - 8900/0
- WHO grade III
- epithelioid haemangioendothelioma - 9133/3
- angiosarcoma - 9120/3
- chondrosarcoma - 9220/3
- Ewing sarcoma / PNET - 9364/3
- fibrosarcoma - 8810/3
- Kaposi sarcoma - 9140/3
- leiomyosarcoma - 8890/3
- liposarcoma (intracranial) - 8850/3
- osteosarcoma - 9180/3
- rhabdomyosarcoma - 8900/3
- undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma - 8830/3
Melanocytic lesions
- meningeal melanocytosis - 8728/0
- meningeal melanocytoma - 8728/1
- meningeal melanoma - 8720/3
- meningeal melanomatosis - 8728/3
Lymphomas
- diffuse large B-cell lymphoma of the CNS - 9680/3
- immunodeficiency-associated CNS lymphomas
- AIDS-related diffuse large B-cell lymphoma
- EBV-positive diffuse large B-cell lymphoma, NOS
- lymphomatoid granulomatosis - 9766/1
- intravascular large B-cell lymphoma - 9712/3
- low grade B-cell lymphomas of the CNS
- T-cell and NK/T-cell lymphomas of the CNS
- anaplastic large cell lymphoma
- ALK-positive - 9714/3
- ALK-negative - 9702/3
- MALT lymphoma of the dura - 9699/3
Histiocytic tumours
- Erdheim-Chester disease - 9750/1
- histiocytic sarcoma - 9755/3
- juvenile xanthogranuloma
- Langerhans cell histiocytosis - 9751/3
- Rosai-Dorfman disease
Germ cell tumours
- choriocarcinoma - 9100/3
- embryonal carcinoma - 9070/3
- germinoma - 9064/3
- mixed germ cell tumours - 9085/3
-
teratoma
- mature - 9080/0
- immature - 9080/3
- with malignant transformation - 9084/3
- yolk sac tumour - 9071/3
Tumours of the sellar region
- WHO grade I
-
craniopharyngioma - 9350/1
- adamantinomatous - 9351/1
- papillary - 9352/1
- granular cell tumour - 9582/0
- pituicytoma - 9432/1
- spindle cell oncocytoma - 8291/0
-
craniopharyngioma - 9350/1
Entities removed
The following entities are no longer found in the 2016 WHO classification, last seen in the 2007 version.
- gliomatosis cerebri - 9381/3
- protoplasmic astrocytoma - 9410/3
- fibrillary astrocytoma - 9420/3
- primitive neuroectodermal tumour (PNET) - 9473/3
- ependymoblastoma - 9392/3
- cellular variant of ependymoma
Although oligoastrocytomas remain entities they are now going to be rare, requiring molecularly distinct populations of both components: astrocytes (IDH-mutant, ATRX-mutant, 1p19q-intact) and oligodendroglial cells (IDH-mutant, ATRX-wildtype, 1p19q-co-deleted) 3.
New entities
The following entities have been introduced in the 2016 WHO classification.
- epithelioid glioblastoma - 9440/3
- diffuse leptomeningeal glioneuronal tumour - no IDC-O code
- diffuse midline glioma, H3K27M-mutant
- embryonal tumor with multilayered rosettes - 9478/3
- ependymoma RELA fusion-positive - 9396/3
- medulloblastoma - WNT - 9475/3
-<p>The <strong>WHO classification of CNS tumours</strong> is the most widely accepted system for classifying CNS tumours and was based on the <a href="/articles/who-grading-of-cns-tumours">histological characteristics</a> of the tumour. Although most recent version of the 'blue book' is the 4<sup>th </sup>edition from 2007, an update has been released in 2016 <sup>3</sup>, which should be considered a replacement of the earlier version. "At this point, a decision to undertake the 5<sup>th </sup>edition series of WHO Blue Books has not been made" <sup>3</sup>. This 2016 update has, for the first time, included molecular parameters into the diagnostic schema, and in fact has elevated them in some instances above histological features <sup>3</sup>. </p><p>This is a fairly dry article, primarily for reference. For more readable versions, see the article on <a href="/articles/brain-tumours">brain tumours</a> and <a href="/articles/brain-tumours-in-infancy">brain tumours in infancy</a> for general discussion of these topics.</p><h4>Main changes since previous (2007) version</h4><p>The most recent update (2016) has significantly changed the classification of a number of tumour families, introducing a greater reliance on molecular markers. The most notable changes involve diffuse gliomas, in which <a href="/articles/isocitrate-dehydrogenase-idh">IDH</a> status (mutated vs wildtype) and 1p19q co-deletion (for oligodendrogliomas) have risen to prominence. Importantly if histological phenotype and genotype are not-concordant (e.g. looks like diffuse astrocytoma but is 1p19q co-deleted, ATRX-wildtype) then genotype wins and it is used to determine diagnosis <sup>3</sup>. </p><p>Medulloblastomas have also been divided into distinct molecular subgroups. </p><p>Another change is the combining of solitary fibrous tumours of the dura with hemangiopericytoma, which although appearing very different on imaging seem now to be manifestations of the same tumour. </p><h4>Classification</h4><h6>Explanatory notes</h6><ul>- +<p>The <strong>WHO classification of CNS tumours</strong> is the most widely accepted system for classifying CNS tumours and was based on the <a href="/articles/who-grading-of-cns-tumours">histological characteristics</a> of the tumour. Although the most recent version of the 'blue book' is the 4<sup>th </sup>edition from 2007, an update has been released in 2016 <sup>3</sup>, which should be considered a replacement of the earlier version. "At this point, a decision to undertake the 5<sup>th </sup>edition series of WHO Blue Books has not been made" <sup>3</sup>. This 2016 update has, for the first time, included molecular parameters into the diagnostic schema, and in fact has elevated them in some instances above histological features <sup>3</sup>. </p><p>This is a fairly dry article, primarily for reference. For more readable versions, see the article on <a href="/articles/brain-tumours">brain tumours</a> and <a href="/articles/brain-tumours-in-infancy">brain tumours in infancy</a> for general discussion of these topics.</p><h4>Main changes since previous (2007) version</h4><p>The most recent update (2016) has significantly changed the classification of a number of tumour families, introducing a greater reliance on molecular markers. The most notable changes involve diffuse gliomas, in which <a href="/articles/isocitrate-dehydrogenase-idh">IDH</a> status (mutated vs wildtype) and 1p19q co-deletion (for oligodendrogliomas) have risen to prominence. Importantly if histological phenotype and genotype are not-concordant (e.g. looks like diffuse astrocytoma but is 1p19q co-deleted, ATRX-wildtype) then genotype wins and it is used to determine diagnosis <sup>3</sup>. </p><p>Medulloblastomas have also been divided into distinct molecular subgroups. </p><p>Another change is the combining of solitary fibrous tumours of the dura with hemangiopericytoma, which although appearing very different on imaging seem now to be manifestations of the same tumour. </p><h4>Classification</h4><h6>Explanatory notes</h6><ul>
Systems changed:
- Spine